0.48
-4.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About EchoIQ
Its shares trade on ASX under the ticker EIQ.AX. It has been listed since 17 December 2010. In the fiscal year to 30 June 2025, it reported revenue of A$101,400 and a net loss of A$13.3m. At that date it held total assets of A$23.4m and shareholders' equity of A$22.8m.
EchoIQ Ltd. engages in the development, marketing and commercialization of software, products and services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2010-12-17. The firm is engaged in the product development, marketing and commercialization of software products and services. The company provides cardiac diagnostics technology. The firm has developed cloud-based decision-support software, EchoSolv, powered by artificial intelligence (AI) and machine learning, which aims to provide physicians with a reliable tool to identify patients at-risk of structural heart disease. ECHOiQ’s technology uses AI assisted diagnostics to deliver real-world health solutions. Its screening program uses an AI backed system and access to cardiac big data that identifies patients at risk from aortic stenosis and other forms of structural heart disease. The firm's technology addresses aortic stenosis, heart failure, and mitral and tricuspid regurgitation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Information Technology
- Industry
- Software
- Listed since
- 17 Dec 2010
- Website
- echoiq.ai ↗
Leadership
Pay as last reported
- Mr. Andrew GroverExecutive Chairman of the Board, since 2019A$1.0m
- Mr. Donald FowlerPresident, Echo IQ USA
- Mr. Philip WoolffChief Operating Officer
- Mr. Sean BrycelandChief Technology Officer
- Mr. Sam DribinChief Technology Officer
- Mr. Jessamyn LyonsJoint Company Secretary
- Mr. Steven FormicaNon-Executive DirectorA$648,621
- Mr. Ken NelsonNon-Executive Director
- Mr. Steve PictonNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- EchoSolv is cloud-based decision-support software powered by artificial intelligence and machine learning.
- The firm provides cardiac diagnostics technology to identify patients at risk of structural heart disease.
- AI assisted diagnostics deliver real-world health solutions using cardiac big data for screening programs.
Weaknesses
- The company is headquartered in Sydney, New South Wales, which may limit local market reach.
- EchoIQ Ltd went public on 17 December 2010, indicating a long history of market exposure.
- The business description repeats the focus on software products and services without adding new details.
Opportunities
- The technology addresses aortic stenosis, heart failure, and mitral and tricuspid regurgitation for broader treatment.
- Physicians can use EchoSolv as a reliable tool to identify patients at risk of disease.
- AI backed systems access cardiac big data to improve screening accuracy for structural heart issues.
Threats
- EchoIQ Ltd operates in the Information Technology sector, which faces rapid technological obsolescence risks.
- The company is listed in Australia, exposing it to specific regional economic fluctuations and volatility.
- Reliance on artificial intelligence for diagnostics creates potential liability if algorithms produce inaccurate medical results.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.